CBIO
Crescent Biopharma
CBIO
CBIO
43 hedge funds and large institutions have $31.7M invested in Crescent Biopharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Holders
43
Holding in Top 10
–
Calls
$132K
Puts
$3K
Top Buyers
| 1 | +$100K | |
| 2 | +$44.4K | |
| 3 | +$21K | |
| 4 |
IP
Intellectus Partners
San Francisco,
California
|
+$11.4K |
| 5 |
CBA
Coastal Bridge Advisors
Westport,
Connecticut
|
+$11K |
Top Sellers
| 1 | -$483K | |
| 2 | -$334K | |
| 3 | -$328K | |
| 4 |
Two Sigma Advisers
New York
|
-$303K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$247K |